nFusz Engages LHA for Strategic Investor Relations Services
HOLLYWOOD, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- nFusz, Inc. (OTCQB:FUSZ), the Hollywood-based digital technology company, announced it has retained LHA, a strategic investor relations agency, to manage the company’s investor relations program.
“We are excited to be partnering with LHA in our investor relations effort,” said nFusz CEO, Rory J. Cutaia. “LHA has the experience and expertise to assist us with adopting best practices and implementing strategies to raise nFUSz’s visibility and awareness within the institutional investment community.”
LHA Investor Relations Partner Keith Lippert said: “nFusz has groundbreaking interactive video technology. We are pleased to be working with the team.”
About nFusz, Inc.
nFusz, Inc. (FUSZ) is a Hollywood-based digital tech company. Our proprietary next-generation interactive video technology is the core of our cloud-based, Software-as-a-Service (SaaS) products. Our flagship product, notifiCRM, is a subscription-based Customer Relationship Management (CRM), sales/lead generation, and social engagement platform compatible with all mobile and desktop devices. Leveraging the power of our interactive video technology, notifiCRM does the selling for you, effectively eliminating sales skill from the sales process. Customers report up to a 600% increase in conversion rates. Our platform can accommodate any size campaign or sales organization, and it’s enterprise-class scalable to meet the needs of today’s global organizations. For more information on nFusz, Inc., visit www.nFusz.com.
About LHA
LHA partners with public and private companies to implement custom-designed, strategic IR programs utilizing industry best practices. Founded in 1984 with headquarters in New York and offices in Los Angeles and San Francisco, LHA is comprised of seasoned professionals working in teams who are committed to serving small-cap companies across multiple industry sectors. Market capitalizations of LHA’s clients range from under $100 million to over $10 billion.
CONTACT INFORMATION
LHA Investor Relations, Kirsten Chapman/Moriah Shilton 415-433-3777 nfusz@lhai.com
© 2018 GlobeNewswire, Inc. All Rights Reserved.
FDA Approves Aurinia Pharmaceuticals' (Nasdaq: AUPH / TSX: AUP) LUPKYNIS (voclosporin) for Adult Patients with Active Lupus Nephritis
